Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax DDI with Ethinyl Estradiol/Levonorgestrel in NHL
NCT03557619Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2019
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in non-Hodgkin lymphoma (NHL), sponsored by AbbVie Inc. Primary endpoints: Time to Maximum Plasma Concentration (Tmax) of Venetoclax, Time to Maximum Plasma Concentration (Tmax) of Ethinyl Estradiol/Levonorgestrel and 7 more. Started Jul 2019; status: recruiting.
02
Drugs
venetoclax
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03557619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557619.